First Community Trust NA Buys 455 Shares of Hologic, Inc. (NASDAQ:HOLX)

First Community Trust NA grew its stake in Hologic, Inc. (NASDAQ:HOLX) by 2.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,165 shares of the medical equipment provider’s stock after purchasing an additional 455 shares during the quarter. Hologic makes up about 0.9% of First Community Trust NA’s holdings, making the stock its 25th largest position. First Community Trust NA’s holdings in Hologic were worth $1,237,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Benson Investment Management Company Inc. purchased a new position in Hologic during the fourth quarter worth about $4,832,000. GAMMA Investing LLC boosted its stake in shares of Hologic by 17.9% in the 3rd quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock worth $312,000 after buying an additional 582 shares during the last quarter. Clean Yield Group grew its holdings in shares of Hologic by 18.9% in the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock valued at $3,291,000 after acquiring an additional 7,266 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Hologic by 2.9% during the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after acquiring an additional 800 shares during the last quarter. Finally, Versor Investments LP bought a new stake in Hologic during the third quarter worth $1,677,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.75% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Evercore ISI boosted their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Needham & Company LLC restated a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Monday. Royal Bank of Canada boosted their target price on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Finally, Morgan Stanley decreased their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday. Seven analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $88.92.

Hologic Price Performance

Hologic stock opened at $70.20 on Wednesday. The firm has a market capitalization of $15.93 billion, a P/E ratio of 21.08, a PEG ratio of 2.32 and a beta of 0.97. Hologic, Inc. has a one year low of $69.46 and a one year high of $84.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The business has a fifty day moving average price of $75.61 and a 200-day moving average price of $78.53.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same quarter last year, the company earned $0.89 EPS. The firm’s revenue was up 4.5% compared to the same quarter last year. As a group, equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.